Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HR010
- Development stage
- Phase 1
- Lead developer
- Shanghai HRAIN Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HR010 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting CD70, a member of the tumor necrosis factor (TNF) receptor superfamily. Developed by Shanghai Hengrun Dasheng Biotech, HR010 is designed to treat CD70-positive tumors, specifically advanced or metastatic clear cell renal cell carcinoma (ccRCC). CD70 is highly expressed in ccRCC but has limited expression in normal tissues, making it a viable target for immunotherapy. The therapy involves genetically modifying a patient's T cells to express a CAR that recognizes and binds to CD70 on the surface of cancer cells, leading to T-cell activation and tumor cell lysis.
- Other names
- anti-human CD70 CAR-T cell injection
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on HR010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HR010.